Trial Profile
A randomized, open-label study of therapy with PEGASYS vs Roferon-A, both with ribavirin + amantadine, on sustained virological response in patients with chronic hepatitis C viral infection unresponsive to standard therapy with interferon alpha plus ribavirin.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Jun 2010
Price :
$35
*
At a glance
- Drugs Interferon alpha-2a (Primary) ; Peginterferon alfa-2a (Primary) ; Amantadine; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms BeTTy
- Sponsors Roche
- 19 Feb 2008 New trial record.